Mohamed Elshenawy, who serves as the Chief Technology Officer for Hims & Hers Health, Inc., recently completed a transaction involving the sale of company equity. According to filings, Elshenawy sold 30,040 shares of Class A Common Stock on June 17, 2026. The transaction was executed at a price of $31.50 per share, resulting in a total value of $946,260. This specific sale was carried out in accordance with a Rule 10b5-1 trading plan that Elshenawy established on December 1, 2025. The adoption of such a plan typically indicates a pre-arranged schedule for trading, designed to comply with securities regulations regarding insider transactions.
Just two days prior to this sale, on June 15, 2026, Elshenawy was involved in more complex equity movements related to his compensation. The executive disposed of 151,534 shares of Class A Common Stock on that date. These shares were not sold for profit but were withheld by the issuer specifically to cover tax withholding obligations associated with the vesting and settlement of his Restricted Stock Units. The value of these withheld shares was reported at $4,571,780, with the tax withholding occurring at a price of $30.17 per share.
Simultaneously with the tax withholding event, Elshenawy acquired a substantial number of new shares. On June 15, 2026, he received a total of 282,597 shares of Class A Common Stock through the vesting of Restricted Stock Units. These RSUs represent a contingent right to receive one share of Class A Common Stock for each unit held. The acquisition occurred at a price of $0 per share upon vesting, reflecting the nature of equity compensation where shares are granted rather than purchased outright.
The vesting structure for these units was detailed in the reporting. A significant portion of these RSUs, totaling 259,084 units, vested as part of a service-based vesting requirement that was satisfied over a four-year period. Of this amount, 25% vested on June 15, 2026, with the remaining 75% scheduled to vest in substantially equal quarterly installments thereafter. Additionally, 23,513 RSUs also vested on June 15, 2026, as part of a separate four-year service-based vesting schedule that also utilizes substantially equal quarterly installments.
These executive transactions occur within a broader context of corporate developments and market analysis for Hims & Hers Health. The company has recently seen shifts in analyst coverage. Barclays raised its price target for the stock from $29 to $39, while maintaining an Overweight rating. This upgrade follows a reported partnership with Novo Nordisk, which has allegedly driven significant increases in website traffic over recent months. Concurrently, Canaccord Genuity reiterated a Buy rating with a $32 price target, pointing to the company's expansion into preventive health and peptide treatments as key growth drivers. In contrast, Leerink has maintained a Market Perform rating with a $25 price target, citing the company's pending regulatory decision regarding the inclusion of peptides on the FDA's 503A Bulk List as a factor in its assessment.
On the governance front, Hims & Hers Health held its recent annual meeting where shareholders elected nine directors. Each nominee received votes ranging from 1.50 billion to 1.51 billion, indicating strong shareholder support for the board composition. The company also announced the appointment of Dr. Anant Vinjamoori as Chief Medical Officer. Dr. Vinjamoori will be responsible for overseeing clinical guidance across various health categories, a move that underscores the company's focus on its evolving strategic initiatives in the healthcare sector.